Strengthening Your COVID-19 Management Technique
Exercising Best Practices for Hospitalized Patients
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health.
Clinical management of COVID-19: living guideline.
World Health Organization.
Clinician Resources
Trends in number of COVID-19 cases and deaths in the US reported to CDC, by state/territory.
Centers for Disease Control and Prevention.
Dexamethasone prescribing information.
US Food and Drug Administration (FDA).
Highlights of prescribing information: Veklury® (remdesivir).
FDA.
Actrema (tocilizumab) prescribing information.
Genentech.
Olumiant (baricitinib) prescribing information.
Lilly.
Suggested Readings
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F, Bouscambert-Duchamp M, Hites M, et al. Lancet Infect Dis. 2022;22(2):209-221.
Long COVID risk and pre-COVID vaccination: an EHR-based cohort study from the RECOVER program.
Brannock MD, Chew RF, Preiss AJ, et al. Preprint. Posted online October 7, 2022. medRxiv. 2022:2022.10.06.22280795.
Persistent presence of spike protein and viral RNA in the circulation of individuals with post-acute sequelae of COVID-19.
Craddock V, Mahajan A, Krishnamachary B, et al. Preprint. Posted online August 9, 2022. medRxiv. 2022:2022.2008.2007.22278520.
Dexamethasone in hospitalized patients with Covid-19.
Horby P, Lim WS, Emberson JR, et al. N Engl J Med. 2021;384(8):693-704.
Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS, Lee JY, Yang JW, et al. Theranostics. 2021;11(1):316-329.
A review of COVID-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and dyslipidemia.
Makhoul E, Aklinski JL, Miller J, et al. Cureus. 2022;14(7):e27438.
Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of coronavirus disease 2019 (COVID-19) patients requiring supplemental O2 therapy: a prospective controlled nonrandomized study.
Marrone A, Nevola R, Sellitto A, et al. Clin Infect Dis. 2022;75(1):e403-e409.
Infliximab for treatment of adults hospitalized with moderate or severe Covid-19.
O’Halloran JA, Kedar E, Anstrom KJ, et al. Preprint. Posted online September 26, 2022. medRxiv. 2022:2022.2009.2022.22280245.
Hospitalization and mortality among Black patients and White patients with Covid-19.
Price-Haywood EG, Burton J, Fort D, et al. N Engl J Med. 2020;382(26):2534-2543.
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Lancet. 2021;397(10285):1637-1645.
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group. Lancet. 2022;400(10349):359-368.
The association of baseline plasma SARS-CoV-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19.
Rogers AJ, Wentworth D, Phillips A, et al. Ann Intern Med. 2022;175(10):1401-1410.
Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial.
Tomazini BM, Maia IS, Cavalcanti AB, et al. JAMA. 2020;324(13):1307-1316.
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q, Iketani S, Li Z, et al. Cell. 2023;186(2):279-286.
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
WHO Solidarity Trial Consortium. Lancet. 2022;399(10339):1941-1953.
Nirmatrelvir and the risk of post-acute sequelae of COVID-19.
Xie Y, Choi T, Al-Aly Z. Preprint. Posted online November 5, 2022. medRxiv. 2022:2022.2011.2003.22281783.
Exercising Best Practices for Patients Hospitalized With COVID-19
Relevant Resources
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
A New Era in Precision Medicine
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
The PCPs Role in Preventing HIV
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
Debates and Discussions About Personalizing Patient Management
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
From Guideline Recommendations to Daily Clinical Decision-Making
Hot Topics in HBV, HCV, and NASH
Improving Patient Outcomes Through Shared Clinical Decision Making
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
Digging Deep on Shared Decision-Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
Mechanistic Insights and Emerging Treatment Options
A PrEP Primer
A Foundation for Managed Care
A Focus on Exacerbation Prevention
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Unlocking Novel Paths to Patient Care
Maximizing Your Role to Impact Patient Outcomes
Evolving Best Practices for Patient Management
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
Informing the Future of NASH Diagnosis and Assessment
A PEP/PrEP Training Guide for Pharmacists
The Increasing Role of JAK Inhibitors
Shared Decision-making in the Era of Biologics
New Pathways to Patient Management
From Comprehensive Patient Evaluations to Individualized Evidence-based Care
Preventing COPD Exacerbations to Improve Outcomes
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Evolving Best Practices for Pediatric Patients
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
New Pathways to Optimize Patient Outcomes
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
An Updated Clinician’s Guide to Assessment and Management
Debates and Discussions About New Upstream Treatment Avenues
A Case-Based Update on Pediatric Patients
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Best Practices for Screening, Diagnosis, and Management
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies
From the Airway Epithelium to Improved Patient Outcomes
Accelerating Diagnosis and Treatment
